STOCK TITAN

Predictive Oncology Inc - POAI STOCK NEWS

Welcome to our dedicated page for Predictive Oncology news (Ticker: POAI), a resource for investors and traders seeking the latest updates and insights on Predictive Oncology stock.

Overview

Predictive Oncology Inc (NASDAQ: POAI) is an innovative, AI-driven biomedical platform specializing in personalized cancer therapies and precision oncology. The company integrates cutting-edge artificial intelligence, machine learning, and bioinformatics with clinical data to revolutionize drug discovery and biomarker prediction. By harnessing AI-driven strategies, the firm aims to enhance the accuracy of treatment selection and improve patient outcomes in the evolving landscape of cancer research.

Business Model and Operations

At its core, Predictive Oncology Inc operates across multiple strategic segments designed to address distinct facets of oncology research and clinical laboratory work. The firm has built proprietary capabilities across several domains:

  • Pittsburgh Segment: This division is focused on comprehensive data analytics through a proprietary biobank containing over 150,000 tumor samples collected over decades. Utilizing an in-house AI/ML platform, the Pittsburgh segment not only generates drug response predictions but also builds advanced 3D cell culture models to simulate tumor behavior in controlled environments.
  • Birmingham Segment: Focused on contract research, this segment provides essential support in solubility testing, stability studies, and protein production. These foundational services contribute to the broader research ecosystem by allowing efficient refinement of biologic formulations.
  • Eagan Segment: With the production of the FDA-cleared STREAMWAY System, this segment offers automated medical fluid waste management and patient-to-drain fluid disposal solutions. It represents the segment with the highest revenue contribution and underscores the company’s commitment to clinical excellence and regulatory compliance.

Technological Innovations

Predictive Oncology stands out due to its deep technological integration. The company leverages its robust AI platform to process vast datasets including multi-omic, genomics, digitized pathology, and phenotypic profiles. Key technological highlights include:

  • AI/ML Platform: Known for its predictive power, the PEDAL platform has been scientifically validated to forecast tumor response to various drug compounds with remarkable accuracy. This capability allows practitioners and researchers to fine-tune therapeutic approaches early in the drug development process.
  • Biobank and Data Repository: The company’s expansive repository, enriched through decades of clinical and laboratory data, forms the backbone of its research efforts. The biobank includes cryopreserved tumor samples and thousands of pathology slides, ensuring that predictive models have a rich data foundation.
  • 3D Cell Culture Models: Utilizing state-of-the-art 3D cell culture techniques, the company creates patient-derived tumor models that more accurately replicate in vivo conditions. This innovation supports drug screening and personalized medicine by capturing the intricacies of tumor heterogeneity.
  • Clinical Lab Capabilities: With its CLIA-certified laboratories, Predictive Oncology maintains high standards of diagnostic testing and validation, ensuring that its data sets are both clinically reliable and reproducible over long periods.

Industry Position and Market Significance

Operating at the intersection of biotechnology and digital health, Predictive Oncology has secured a unique position within the precision medicine market. Its integration of AI-driven analytics with a comprehensive clinical asset base allows the company to contribute meaningfully to drug discovery efforts in oncology. This integration enables the identification of novel biomarkers and supports de-risking strategies in drug development by addressing patient heterogeneity from the earliest stages of testing.

The company's diverse portfolio not only provides robust support to academic and industrial partners but also addresses critical needs in the competitive landscape of personalized cancer therapy. Its collaborative initiatives with key stakeholders in the pharmaceutical, diagnostic, and biotech sectors further underscore its commitment to advancing cancer treatment research.

Key Attributes and Value Proposition

Predictive Oncology Inc is recognized for its:

  • Comprehensive Data Assets: A vast collection of clinically validated tumor samples and pathology slides enables precise modeling of drug responses and biomarker discovery, offering an expansive resource for precision oncology research.
  • Technological Integration: The seamless integration of AI, machine learning, and clinical experimentation positions the company as a bridge between advanced data analytics and clinical applications in oncology.
  • Regulatory and Clinical Excellence: With a wholly owned CLIA lab and FDA-cleared systems, the company adheres to rigorous clinical standards, ensuring the reproducibility and accuracy of its data and research outcomes.
  • Broad Industry Collaborations: Through partnerships with pharmaceutical companies, biotech firms, and research institutions, Predictive Oncology leverages diverse expertise to elevate the standard of personalized cancer therapy research.

Scientific and Research Applications

Scientific inquiry at Predictive Oncology is driven by a commitment to deep data analysis and clinical validation. The company's research scope spans:

  • Biomarker Discovery: By utilizing multi-omic data and retrospective analyses, the company identifies key features that inform patient outcomes and drug efficacy. This approach supports the development of clinical decision support tools and personalized treatment protocols.
  • Drug Repurposing and Screening: Employing high-throughput AI models, the company efficiently evaluates both existing and novel compounds. Its data-driven methods allow for rapid iterative testing that reduces the time required for preliminarily assessing drug candidates.
  • Patient-Derived Tumor Models: The creation of advanced 3D cell culture systems grounded in live cell data paves the way for more physiologically relevant examination of drug responses, ultimately contributing to tailored therapeutic strategies.

Operational Excellence and Data Integrity

Reliability and precision are at the heart of Predictive Oncology’s operational framework. Every step of the process, from sample collection and data curation in its biobank to AI model validation in CLIA-certified labs, is done with stringent quality controls. This unwavering emphasis on data integrity supports both the scientific research and the clinical applications of the company’s offerings. Detailed longitudinal records and stringent testing protocols ensure that historical data remains robust and relevant, a critical factor when building predictive models that support personalized therapy decisions.

Conclusion

In summary, Predictive Oncology Inc represents a convergence of advanced data science, artificial intelligence, and clinical expertise in oncology. Its multidimensional approach—spanning AI-driven drug discovery, personalized treatment profiling, and rigorous clinical validation—positions the company as a vital contributor to innovation in personalized cancer therapy research. With comprehensive resources that include an extensive biobank, state-of-the-art laboratory capabilities, and a diversified operational structure, the company provides a rich, data-driven foundation for transforming how cancer is diagnosed and treated. This informed, methodical integration of technology and clinical science not only fosters advancements in the field but also underscores the company’s contribution to shaping future standards in precision medicine and oncology research.

Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) has achieved a significant milestone with its PeDAL platform through the Discovery 21 campaign, which validated the platform's ability to make high-confidence predictions on ovarian tumor samples. The PeDAL platform demonstrated a drug response prediction accuracy of 91.8% across 175 FDA-approved drugs and 130 tumor samples. This breakthrough is expected to attract pharmaceutical partnerships and enhance drug discovery efficiency, aligning with the company’s mission of optimizing cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) aims to lead in the AI drug discovery market, projected to reach $20 billion within three years. The company plans to market its PeDAL™ platform, having completed successful evaluations, which enhance treatment predictions for specific cancers. POAI anticipates establishing new partnerships and generating revenue from PeDAL-powered projects this year. The development costs for new oncology drugs exceed $35M, making efficient drug discovery crucial. With a database of over 150,000 tumors, POAI employs AI to optimize cancer treatments and improve patient outcomes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1%
Tags
none
-
Rhea-AI Summary

Predictive Oncology Inc. (NASDAQ: POAI) announced preliminary results from its Discovery 2021 program, highlighting its AI-driven CoRE™ program's ability to identify potential new uses for chemotherapy drugs in ovarian cancer. The integration of Helomics' data with the PeDAL™ (Patient-centric Discovery by Active Learning) initiative allowed for predictions on drug efficacy across various cancers. PeDAL demonstrated confident predictions from a limited sample, potentially reducing drug development costs for partners. The company emphasizes its multiomic approach to personalized cancer therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.64%
Tags
none
Rhea-AI Summary

Predictive Oncology (Nasdaq: POAI) held its Annual Meeting of Stockholders on December 23, 2021, but it was adjourned due to insufficient quorum. Only 46% of the shares entitled to vote were represented. The meeting has been rescheduled for December 30, 2021, to allow more stockholders to participate. Stockholders of record as of October 26, 2021, are encouraged to vote before December 29, 2021. The company continues to solicit votes during this period. The proxy statement detailing voting proposals is available on the SEC website and the company's investor relations page.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.22%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (POAI) is enhancing its capabilities through the acquisition of zPREDICTA, a leader in cancer solutions, known for its patented 3D cell culture platform. This strategic move aims to expand POAI's reach in personalized cancer therapies, leveraging zPREDICTA's established revenue streams and client base in pharmaceutical sectors. The acquisition, alongside the hiring of Pamela Bush to lead sales efforts, supports POAI's transition from R&D to a revenue-generating biopharmaceutical company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.21%
Tags
none
-
Rhea-AI Summary

Predictive Oncology (POAI) has announced the appointment of Pamela Bush, Ph.D., MBA, as SVP of Strategic Sales and Business Development. With nearly 20 years of experience, Bush aims to commercialize the company's innovative cancer research technologies. CEO Mel Engle highlighted her role in optimizing treatment predictions for pharmaceutical and healthcare partners. Additionally, Bush will assist in business development and integrate the recently acquired zPREDICTA into the company's offerings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.12%
Tags
none
Rhea-AI Summary

Predictive Oncology (POAI) has acquired zPREDICTA, enhancing its portfolio with a patented 3D cell culture platform aimed at improving cancer therapy development. This acquisition is expected to provide an immediate revenue stream and long-term growth due to anticipated synergies. zPREDICTA specializes in tumor-specific models that closely mimic human cancer environments, which is vital for drug discovery. The integration of zPREDICTA’s technology with Predictive Oncology's AI-driven database promises to enhance treatment outcome predictions, delivering greater insights for pharmaceutical partners.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
-
Rhea-AI Summary

Predictive Oncology (POAI) reported its Q3 2021 financial results, highlighting a reduced loss per share of $0.08 from $0.46 in Q3 2020. Revenue for the quarter was $313,663, down from $480,757 year-over-year, primarily due to decreased sales of STREAMWAY System units. Cash increased significantly to $41 million for the nine months ended September 30, 2021, compared to $2.3 million in 2020. The company has no outstanding debt and reported operational cash usage decreased. The gross profit margin remained steady at approximately 65%.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.74%
Tags
-
Rhea-AI Summary

Predictive Oncology is advancing cancer research via AI technologies aimed at improving drug discovery and clinical outcomes. As of October 19, 2021, the company launched a new website showcasing its mission and subsidiaries: Helomics, Soluble Biotech, and TumorGenesis. These entities work collaboratively to predict treatment outcomes and develop optimized cancer drugs. Helomics utilizes a vast database and AI for personalizing therapies, while Soluble Biotech streamlines protein formulation. TumorGenesis focuses on studying ovarian cancer cells for better treatment insights.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.56%
Tags
none
Rhea-AI Summary

Predictive Oncology (NASDAQ: POAI) announced the election of Raymond F. Vennare to its Board of Directors effective September 13, 2021. Vennare has over 30 years of experience in biotechnology and has held leadership positions in multiple companies, including as CEO of Cvergenx, Inc. His expertise spans company creation, technology commercialization, and corporate governance. CEO J. Melville Engle expressed excitement about Vennare joining the board, stating he will provide valuable perspective and leadership in oncology.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.61%
Tags
management

FAQ

What is the current stock price of Predictive Oncology (POAI)?

The current stock price of Predictive Oncology (POAI) is $1.48 as of April 1, 2025.

What is the market cap of Predictive Oncology (POAI)?

The market cap of Predictive Oncology (POAI) is approximately 10.7M.

What is the core focus of Predictive Oncology Inc?

Predictive Oncology Inc specializes in using artificial intelligence to drive personalized cancer therapies, biomarker discovery, and advanced drug discovery processes through its extensive clinical and molecular data assets.

How does the company generate revenue?

The company operates through distinct segments including AI-driven drug discovery and 3D tumor modeling, contract research in solubility and stability studies, and the production of FDA-cleared clinical lab systems, each contributing to its diversified revenue streams.

What are the primary technological innovations employed by the company?

Its innovations include a proprietary AI/ML platform for predictive modeling, a vast biobank of tumor samples and pathology slides, and advanced 3D cell culture models that better simulate the in vivo environment for accurate drug response testing.

How does Predictive Oncology contribute to personalized medicine?

The company leverages its integrated approach by combining large-scale clinical data with AI analytics, enabling the development of predictive models that tailor cancer therapies to individual patient profiles and improve treatment outcomes.

What competitive advantages does Predictive Oncology hold in its industry?

Its competitive edge lies in its comprehensive clinical and molecular dataset, validated AI platform, and integrated laboratory capabilities. These aspects enable robust drug response predictions and biomarker discovery, setting it apart in the personalized oncology landscape.

How does the company ensure data integrity and clinical reliability?

Predictive Oncology maintains high standards through its CLIA-certified laboratories and rigorous quality control measures across its biobank. This ensures the reproducibility and accuracy of its predictive models and clinical data.

Who are the primary customers and partners of Predictive Oncology?

The company collaborates with academic institutions, pharmaceutical companies, and biotech firms that require advanced AI tools and clinically validated data for drug discovery, personalized therapy research, and biomarker development.

How does the company address challenges in drug discovery?

By integrating patient heterogeneity early in its AI-driven screening processes and utilizing advanced 3D cell culture methods, Predictive Oncology mitigates common challenges such as late-stage clinical trial failures and enhances the predictability of drug responses.
Predictive Oncology Inc

Nasdaq:POAI

POAI Rankings

POAI Stock Data

10.74M
7.10M
1.55%
3.34%
7.11%
Medical Instruments & Supplies
Orthopedic, Prosthetic & Surgical Appliances & Supplies
Link
United States
PITTSBURGH